Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-Line BiotechNSE:QLINE -1.12%14 Graham Number is ₹161.09 as of Mar. 2025. GuruFocus rates NSE:QLINE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 402 Medical Devices & Instruments companies, Q-Line Biotech ranks worse than 77.11% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-08-13), the stock price of Q-Line Biotech is ₹531.80. Q-Line Biotech's graham number for the quarter that ended in Mar. 2025 was ₹161.09. Therefore, Q-Line Biotech's Price to Graham Number ratio for today is 3.30.
The historical rank and industry rank for Q-Line Biotech's Graham Number or its related term are showing as below:
NSE:QLINE'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0 Med: 0 Max: 3.34
Current: 3.3
During the past 3 years, the highest Price to Graham Number ratio of Q-Line Biotech was 3.34. The lowest was 0.00. And the median was 0.00.
NSE:QLINE's Price-to-Graham-Number is ranked worse than 77.11% of 402
companies
in the Medical Devices & Instruments industry
Industry Median: 1.89
vs NSE:QLINE: 3.30
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Q-Line Biotech (NSE:QLINE) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Q-Line Biotech's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2025 )
=
531.80
/
161.09
=
3.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Q-Line Biotech Graham Number Related Terms
Q-Line Biotech Graham Number Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Graham Number Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Graham Number
106.07
118.17
161.09
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Graham Number
0.00
118.17
161.09
NSE:QLINE vs ABT, SYK, MDT: Graham Number Comparison
For the Medical Devices subindustry, Q-Line Biotech's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Price-to-Graham-Number vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech (NSE:QLINE) has a Graham Number of ₹161.09 as of Mar. 2025. The Graham Number values a company based on its per-share earnings and book value. View historical data on Q-Line Biotech and its competitors. According to the industry distribution chart, Q-Line Biotech ranks #310 out of 402 companies in the Medical Devices & Instruments industry, placing it in the top 77.1%.
Is Q-Line Biotech's Graham Number too high?
Q-Line Biotech's current Graham Number is ₹161.09. Based on the distribution chart, Q-Line Biotech ranks #310 out of 402 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Q-Line Biotech has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Graham Number compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #310 out of 402 companies for Graham Number. This places Q-Line Biotech in the lower half of its industry. The industry median Graham Number is 1.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Medical Devices & Instruments company?
The median Graham Number among Medical Devices & Instruments companies is 1.89, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median Graham Number is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current Graham Number is ₹161.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Graham Number of ₹161.09. The current Graham Number is ₹161.09. Q-Line Biotech's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Graham Number is ₹161.09 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
14GF Score
Get the complete analysis for NSE:QLINE
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 
